Key takeaways
- LDL-C measures the cholesterol carried inside particles; LDL-P and ApoB count the particles themselves.
- Entry and retention in the artery wall is a particle event, so particle count sits closer to the causal variable than cholesterol concentration.
- Discordance means cholesterol per particle has shifted, and it is produced by the triglyceride-rich metabolism of insulin resistance.
- Small dense particles cross the endothelium more readily, bind the wall more avidly, oxidise more easily and circulate longer.
- ApoB is the practical test because every atherogenic particle carries one ApoB molecule, including the remnants LDL-P does not count.
Most people are handed one LDL number and assume it is the LDL number. It is not. LDL-C is a measure of how much cholesterol is being carried inside LDL particles; LDL-P is a count of the particles themselves. In the majority of people the two say roughly the same thing, which is why the distinction stayed academic for decades. In a specific and increasingly common group they disagree — and in that group the standard panel systematically under-reports risk in exactly the people who most need it reported accurately.
Cargo and vehicles
The useful mental model is freight. LDL particles are the lorries; cholesterol is the cargo. LDL-C tells you the total tonnage on the road. LDL-P tells you how many lorries there are.
If every lorry carries the same load, the two figures are interchangeable and you can infer one from the other. If some lorries are running half-empty, the same tonnage requires many more vehicles — and it is the number of vehicles, not the tonnage, that determines how many end up in the wrong place.
That last point is the mechanistic core. An LDL particle enters the arterial wall by crossing the endothelium, and whether it does so depends on the particle being there, not on how much cholesterol it happens to contain. Retention in the subendothelial space is a particle event. So particle count is closer to the causal variable than cholesterol concentration is, and the two only track each other while the cholesterol-per-particle ratio stays constant (Otvos et al., J Clin Lipidol 2011).
Why they come apart
Discordance simply means the cholesterol content per particle has shifted. It goes in both directions.
LDL-C under-reports risk when particles are small and cholesterol-depleted. Many particles, each carrying less, produces an unremarkable LDL-C sitting on top of a high particle count.
LDL-C over-reports risk when particles are large and cholesterol-rich. Fewer particles, each carrying more, produces an LDL-C that looks worse than the particle burden warrants.
The first pattern is far more common and far more consequential, because it is produced by the metabolic state that is itself becoming more common. In cohort data, the people whose LDL-P is high while their LDL-C looks acceptable carry the event risk that their LDL-C failed to flag (Cromwell et al., J Clin Lipidol 2007).
What makes small dense LDL worse
Small dense particles are not merely more numerous for a given cholesterol load. Particle for particle they behave worse (Ivanova et al., Oxid Med Cell Longev 2017):
- They cross the endothelium more readily, because they are smaller
- They bind arterial wall proteoglycans more avidly, so they are retained once they arrive
- They are more susceptible to oxidation, and oxidised LDL is what macrophages take up
- They have reduced affinity for the LDL receptor, so they circulate for longer, which increases the opportunity for both of the above
The formation mechanism is worth knowing because it explains who gets them. When triglyceride-rich VLDL is abundant, cholesteryl ester transfer protein swaps triglyceride into LDL and cholesterol out of it. Hepatic lipase then strips the triglyceride back out, leaving a smaller, denser, cholesterol-poor particle. High triglycerides are therefore not merely a bystander in this pattern — they are the manufacturing process.
Who is discordant
The classic discordant panel belongs to insulin resistance and metabolic syndrome:
- LDL-C normal, or only slightly raised
- Triglycerides high
- HDL-C low
- LDL-P and ApoB elevated
- Predominance of small dense LDL
Read the first line alone and this panel gets signed off. Read all five and it is a high-risk panel. This is the single most consequential blind spot in routine lipid screening, and it falls hardest on people with central adiposity, prediabetes, fatty liver or polycystic ovary syndrome — which is why fasting insulin and insulin resistance belong in the same conversation as the lipid panel rather than in a separate one.
The particles the standard panel ignores entirely
There is a further gap. Calculated LDL-C does not account for the cholesterol carried in triglyceride-rich remnant particles — VLDL and IDL — and those are atherogenic too. In someone with high triglycerides, remnant cholesterol can be a meaningful share of total atherogenic burden while remaining invisible on the line everyone reads (Nordestgaard, Circ Res).
This is the same population again. The metabolic pattern that produces small dense LDL also produces remnants, so the standard panel misses the same person twice.
LDL-P, ApoB, or non-HDL-C
Three ways to get at particle burden, with different practicalities.
| Test | What it counts | Practical position |
|---|---|---|
| LDL-C | Cholesterol inside LDL particles | Universally available; misleading in metabolic dysfunction |
| LDL-P | LDL particles specifically, by NMR | Most granular; less widely available and more expensive |
| ApoB | All atherogenic particles — LDL, VLDL, IDL, Lp(a) | Widely available, standardised, and the practical choice for most people |
| Non-HDL-C | Total cholesterol minus HDL-C | Free on every existing panel; a decent approximation of ApoB |
Every atherogenic particle carries exactly one ApoB molecule, so ApoB is a direct particle count without needing a specialised assay, and it captures the remnants that LDL-P by definition does not. Where the two disagree with LDL-C, ApoB has been the better predictor of events (Sniderman et al., JAMA Cardiol 2019), and the causal role of ApoB-containing lipoproteins in atherosclerosis is about as firmly established as anything in cardiology (Ference et al., Eur Heart J, EAS consensus). ApoB versus LDL-C works through that comparison directly.
The practical answer for most people: order ApoB. Reserve LDL-P for cases where particle-size detail genuinely changes something. And if neither is available, calculate non-HDL-C from the panel you already have — it costs nothing and is far better than LDL-C alone.
The clinical pearl: a normal LDL-C alongside high triglycerides and low HDL is not a reassuring panel. It is the signature of discordance, and it is the exact combination that gets signed off as fine. Anyone with central adiposity, prediabetes or fatty liver should have ApoB measured at least once, because for them the standard panel is measuring the wrong thing.
What changes once you know
Discordance is only worth measuring if it alters something. It does, in three ways.
It reclassifies risk. Someone whose LDL-C says average and whose ApoB says high is in the second category, and the intensity of everything that follows should reflect that rather than the reassuring number.
It changes what you treat first. Discordance is generated by the metabolic state, so the upstream levers — visceral fat, insulin sensitivity, alcohol, refined carbohydrate load, training — act on the manufacturing process rather than on the output. Improving that state raises cholesterol per particle and lowers particle count at the same time, which is why triglycerides and ApoB tend to fall together. The same logic explains the lipid pattern seen on GLP-1 therapy.
It changes what you track. Once ApoB is your metric, a follow-up LDL-C that has not moved is no longer evidence of failure. Track the same marker over time, drawn under the same conditions, and measure Lp(a) once alongside it, since it is inherited and will not change.
What any of this means for an individual, and what should be done about it, is a physician's judgement after evaluation — the 60-second assessment is where that begins.
Bottom line
LDL-C measures cargo; LDL-P and ApoB measure vehicles, and atherosclerosis is driven by vehicles. The two agree in most people and diverge exactly where it matters most — in insulin resistance, where triglyceride-rich metabolism manufactures small, cholesterol-poor particles and a normal-looking LDL-C conceals a high particle count. ApoB is the practical test, because it counts every atherogenic particle including the remnants a standard panel ignores, and non-HDL-C is a free approximation already sitting on your existing results. If your triglycerides are high and your HDL is low, do not accept a normal LDL-C as the end of the conversation.
Educational content, not medical advice. Laboratory interpretation and any treatment decision are made by a licensed physician after individual evaluation. Individual results vary.
